Enteroviral infections with antiCD20 therapies

Abstract

Get full access to this article

View all access options for this article.

References

Alvarez

Longbrake

Rammohan

, et al. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord 2023; 79: 105009.

Banks

Poliakov

Flanagan

, et al. Enterovirus encephalitis in people with multiple sclerosis on ocrelizumab: insights from a multicenter case series. Neurol Neuroimmunol Neuroinflamm 2026; 13(2): e200534.

Hauser

Bar-Or

Cohen

, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383(6): 546–557.

Di Napoli

Balzano

Rafaniello

, et al. Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database. Expert Opin Drug Saf. Epub ahead of print April 23, 2025. DOI: 10.1080/14740338.2025.2493795.

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies. Mult Scler 2026.

Enteroviral infections with antiCD20 therapies—A class effect?

Abstract

Get full access to this article

References